Feed BMY
BM

Bristol-Myers Squibb

BMY · NYSE

$64.09 +0.56% (+$0.36)
1M -0.82%
Market Cap $130.2B
P/E Ratio 14.03x
Div. Yield 3.94%
ROE 46.75%

Bulios Fair Price

$94.84

48.0% upside

Preț actual

$64.09

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile BMY sunt în prezent subevaluate față de prețul lor de piață. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Strong
7/9
Valuation
78 /100
Cheap
P/E 14.03x
P/B 5.84x
EV/EBITDA 9.88x
Growth
31 /100
Declining
EPS growth 5.36%
Book val. growth 15.90%
Rev. growth 1.45%
Profitability
100 /100
Strong
Gross margin 70.16%
FCF margin 23.26%
Net margin 18.87%
Quality
83 /100
Excellent
ROIC 15.47%
Asset turnover 0.56x
ROE 46.75%
Debt
54 /100
Moderate
Debt/Equity 1.93x
Net debt/EBITDA 2.06x
Current ratio 1.53x
Stability
35 /100
Moderate
Beta 0.23x
Profitable years 1
Rev. volatility 5.14%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre BMY
Online

Despre companie

Bristol-Myers Squibb Company (BMY) is an American pharmaceutical company with a global reach. The company specializes in research, development, and manufacturing of drugs and biological products for the treatment of various diseases. Bristol-Myers Squibb focuses its efforts on the treatment of cancer, cardiovascular diseases, immune disorders, and other serious conditions. The company is known for its innovative medications that bring significant medical benefits to patients. Bristol-Myers Squibb has a wide range of drugs on the market, and its products are distributed worldwide. The company also has an active research program aimed at discovering new drugs and therapeutic approaches. Bristol-Myers Squibb Company (BMY) shares are an attractive choice for investors who follow the pharmaceutical sector and seek investment opportunities in a renowned pharmaceutical company with a focus on innovative treatment methods.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Christopher Boerner

Employees

32,500

Headquarters

Princeton

Evenimente viitoare

29 OCT.

Earnings

Upcoming earnings report

43d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.